“It’s always good to hear of new drugs that make a difference to the lives of cancer patients,” the medical press erroneously states about Zelboraf.
Zelboraf was approved in 2011 for use in late-stage (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer. Melanoma is the leading cause of death from skin disease. The National Cancer Institute estimated that 68,130 new cases of melanoma were diagnosed in the United States during 2010; about 8,700 people died from the disease.
Zelboraf, the new expensive drug to treat advanced skin cancer, or metastatic melanoma, allows people to die more slowly, twice as slowly in fact. Instead of dying in about nine months, now those with this deadly cancer can stretch out their suffering for a full six months longer and pay a fortune for the privilege of having their death extended in such a torturous fashion.
“It worked better than chemotherapy,” said Antoni Ribas, a professor of hematology and oncology and researcher at University of California Los Angeles’ Jonsson Cancer Center. Zelboraf will cost $9,400 per month, $56,000 for six months or $112,000 for one year of treatment.
Zelboraf fails to elicit any response in 14% of patients and yet the patients receiving some benefit appear to develop resistance to the treatment over time, but since mainstream medicine has no other effective treatment, with less than 10% showing a response to other available therapies, mainstream oncologists will go with this one.
While taking Zelboraf you should avoid going out in the sun thereby increasing vitamin D deficiency that in turn increases your chances of dying of cancer., Possible serious side effects of Zelboraf include severe allergic reactions, severe skin reactions, and changes in the electrical activity of your heart called QT prolongation, which can be life-threatening. Also abnormal liver function, eye problems, fatigue, diarrhea, hair loss or new melanoma lesions can result. About 26 percent of patients developed a skin-related cancer called cutaneous squamous cell carcinoma, which is reportedly managed with surgery. Other common side effects include joint pain, rash, sunburn or sun sensitivity, nausea, itching, or warts. Zelboraf should be used with caution, if at all, if you are taking any of the following pharmaceutical medicines:
- Blood thinners
- Antifungal medicines
- HIV medicines
- Seizure medicines
- Medicines to treat irregular heartbeat
I see absolutely nothing good about Zelboraf and it is more than amazing that they herd people into taking this drug and that people or insurance companies would pay for it. I am sure that a regimen of both oral and transdermal iodine (Dr. Simoncini in Rome uses iodine to cure skin cancer), heavy use of topical and oral sodium bicarbonate for a specified amount of time, and magnesium medicine combined with cannabinoids  (ingested and/or topical) would be a much more humane form of treatment that would be safer and more effective—to the level of actually giving a person a very real chance of curing himself of this miserable affliction. The cost of such treatments would be approximately $500 a month if a full protocol with natural vitamin C and other important nutrients are included.
Love not Hate in Medicine
Dr. Richard Schulze said to the wife of a patient with liver and pancreas cancer: “The most important part of your husband’s treatment will be his feelings, his attitude, his positive outlook, and his positive affirmations. Over the years I have learned—in my personal healing, my clinical experience and my life experience—that the most powerful healing tool for cancer, and for any disease, is love. So I would give him a huge dose of love every minute of every day.”
People want love—they do not want to be beaten to a pulp by oncologists who follow the pharmaceutical paradigm. What they do is not so different from the medical experiments of I. G. Farben in the concentration camps. Their treatments are poisonous and bring on death at a slightly slower and more torturous rate.
Some people feel that there can be no cure of cancer if the inner state, the soul, is not taken into account and cared for.
Pharmaceutical oncology is acting against the soul, against our bodies, against good common sense and against life itself. Only those with a death wish should seek out doctors who practice this form of medicine for they will be assured of death.
“There’s no remote chance this is going to be a cure. There may be 1% or 2% of patients who remain in very durable remission,” states Kim A. Margolin, MD, who leads melanoma research for the Seattle Cancer Care Alliance. Margolin is also a professor at the University of Washington and a member of the Fred Hutchinson Cancer Research Center, both in Seattle.
 The QT interval represents electrical depolarization and repolarization of the left and right ventricles of the heart. A prolonged QT interval is a biomarker for ventricular tachyarrhythmias like torsades de pointes and a risk factor for sudden death. Treatment of this arrhythmia is directed at withdrawal of the offending agent (often a drug, infusion of magnesium sulfate, antiarhythmic drugs and electrical therapy as needed. Because of the polymorphic (the occurrence in different forms) nature of torsades de pointes, synchronized cardioversion may not be possible, and the patient may require an unsynchronized shock (or defibrillation).
 Melanoma is responsible for the greatest number of skin-cancer-related deaths worldwide. It was reported that CB1 and the CB2 receptors are expressed in normal skin and skin tumors of mice and humans. In vitro studies showed that activation of cannabinoid receptors induced the apoptotic death of tumorigenic epidermal cells, without affecting the nontransformed epidermal cells. Administration of WIN-55,212-2 or the selective CB2 agonist JWH-133 was shown to result in growth inhibition of malignant tumors in nude mice (ref. 6 and references therein). Another study showed that activation of these receptors decreased tumor growth, angiogenesis and metastasis of melanomas in mice, and inhibited proliferation via inhibition of Akt pathway and hypophosphorylation of retinoblastoma in melanoma cells (6). These two studies offer an exciting opportunity to further explore the use of cannabinoids for the treatment and management of melanoma. http://cancerres.aacrjournals.org/content/68/2/339.full